DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32.
Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM. Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Neurology. 2015;85:535–42.
Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019;14:5541–54.
Knopman DS, Amieva H, Petersen RC, Chetelat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7:33.
2023 Alzheimer’s disease facts and figures. Alzheimers Dement 2023;19:1598–695.
Saido T, Leissring MA. Proteolytic degradation of amyloid beta-protein. Cold Spring Harb Perspect Med. 2012;2:a006379.
Liu N, Haziyihan A, Zhao W, Chen Y, Chao H. Trajectory of brain-derived amyloid beta in Alzheimer’s disease: where is it coming from and where is it going? Transl Neurodegener. 2024;13:42.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608.
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330:1774.
Nalivaeva NN, Turner AJ. Targeting amyloid clearance in Alzheimer’s disease as a therapeutic strategy. Br J Pharmacol. 2019;176:3447–63.
Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087–93.
Petralla S, Panayotova M, Franchina E, Fricker G, Puris E. Low-density lipoprotein receptor-related protein 1 as a potential therapeutic target in Alzheimer’s disease. Pharmaceutics. 2024;16:948.
Kang C. Donanemab: first approval. Drugs. 2024;84:1313–8.
Dhillon S. Aducanumab: first approval. Drugs. 2021;81:1437–43.
Hoy SM. Lecanemab: first approval. Drugs. 2023;83:359–65.
Kurochkin IV, Goto S. Alzheimer’s beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 1994;345:33–7.
Mukherjee A, Song E, Kihiko-Ehmann M, Goodman JP Jr, Pyrek JS, Estus S, et al. Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci. 2000;20:8745–9.
Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000;20:1657–65.
Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998;273:32730–8.
Sudoh S, Frosch MP, Wolf BA. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry. 2002;41:1091–9.
Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J Biol Chem. 2000;275:36621–5.
Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer’s disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol. 2003;162:313–9.
Nalivaeva NN, Turner AJ. Role of ageing and oxidative stress in regulation of amyloid-degrading enzymes and development of neurodegeneration. Curr Aging Sci. 2017;10:32–40.
Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol. 2004;164:1425–34.
de Dios C, Bartolessis I, Roca-Agujetas V, Barbero-Camps E, Mari M, Morales A, et al. Oxidative inactivation of amyloid beta-degrading proteases by cholesterol-enhanced mitochondrial stress. Redox Biol. 2019;26:101283.
Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA. 2003;100:4162–7.
Sousa L, Guarda M, Meneses MJ, Macedo MP, Vicente Miranda H. Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases. J Pathol. 2021;255:346–61.
Eckman EA, Eckman CB. Abeta-degrading enzymes: modulators of Alzheimer’s disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans. 2005;33:1101–5.
Imataka H, Sogawa K, Yasumoto K, Kikuchi Y, Sasano K, Kobayashi A, et al. Two regulatory proteins that bind to the basic transcription element (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene. EMBO J. 1992;11:3663–71.
Fan H, Zhang Y, Zhang J, Yao Q, Song Y, Shen Q, et al. Cold-inducible Klf9 regulates thermogenesis of brown and Beige fat. Diabetes. 2020;69:2603–18.
Scobie KN, Hall BJ, Wilke SA, Klemenhagen KC, Fujii-Kuriyama Y, Ghosh A, et al. Kruppel-like factor 9 is necessary for late-phase neuronal maturation in the developing dentate gyrus and during adult hippocampal neurogenesis. J Neurosci. 2009;29:9875–87.
Guo N, McDermott KD, Shih YT, Zanga H, Ghosh D, Herber C, et al. Transcriptional regulation of neural stem cell expansion in the adult hippocampus. Elife. 2022;11:e72195.
Trakhtenberg EF, Li Y, Feng Q, Tso J, Rosenberg PA, Goldberg JL, et al. Zinc chelation and Klf9 knockdown cooperatively promote axon regeneration after optic nerve injury. Exp Neurol. 2018;300:22–9.
Potashkin JA, Bottero V, Santiago JA, Quinn JP. Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer’s patients. PLoS One. 2019;14:e0222921.
Cui Y, Qiao A, Jiao T, Zhang H, Xue Y, Zou Y, et al. The hepatic FOXQ1 transcription factor regulates glucose metabolism in mice. Diabetologia. 2016;59:2229–39.
Cui A, Fan H, Zhang Y, Zhang Y, Niu D, Liu S, et al. Dexamethasone-induced Kruppel-like factor 9 expression promotes hepatic gluconeogenesis and hyperglycemia. J Clin Invest. 2019;129:2266–78.
Kurochkin IV, Guarnera E, Berezovsky IN. Insulin-degrading enzyme in the fight against Alzheimer’s disease. Trends Pharmacol Sci. 2018;39:49–58.
Tian Y, Jing G, Zhang M. Insulin-degrading enzyme: Roles and pathways in ameliorating cognitive impairment associated with Alzheimer’s disease and diabetes. Ageing Res Rev. 2023;90:101999.
Gonzalez-Casimiro CM, Merino B, Casanueva-Alvarez E, Postigo-Casado T, Camara-Torres P, Fernandez-Diaz CM, et al. Modulation of insulin sensitivity by insulin-degrading enzyme. Biomedicines. 2021;9:86.
Quan Q, Li X, Feng J, Hou J, Li M, Zhang B. Ginsenoside Rg1 reduces β‑amyloid levels by inhibiting CDΚ5‑induced PPARγ phosphorylation in a neuron model of Alzheimer’s disease. Mol Med Rep. 2020;22:3277–88.
Li Y, Wu H, Liu M, Zhang Z, Ji Y, Xu L, et al. Polysaccharide from Polygala tenuifolia alleviates cognitive decline in Alzheimer’s disease mice by alleviating Abeta damage and targeting the ERK pathway. J Ethnopharmacol. 2024;321:117564.
Chang KW, Zong HF, Ma KG, Zhai WY, Yang WN, Hu XD, et al. Activation of alpha7 nicotinic acetylcholine receptor alleviates Abeta(1-42)-induced neurotoxicity via downregulation of p38 and JNK MAPK signaling pathways. Neurochem Int. 2018;120:238–50.
Kim Y, Rouse M, Gonzalez-Mariscal I, Egan JM, O’Connell JF. Dietary curcumin enhances insulin clearance in diet-induced obese mice via regulation of hepatic PI3K-AKT axis and IDE, and preservation of islet integrity. Nutr Metab. 2019;16:48.
Lifshitz V, Benromano T, Weiss R, Blanga-Kanfi S, Frenkel D. Insulin-degrading enzyme deficiency accelerates cerebrovascular amyloidosis in an animal model. Brain Behav Immun. 2013;30:143–9.
Liu Y, Liu L, Lu S, Wang D, Liu X, Xie L, et al. Impaired amyloid beta-degrading enzymes in brain of streptozotocin-induced diabetic rats. J Endocrinol Invest. 2011;34:26–31.
Zhao K, Liu J, Sun T, Zeng L, Cai Z, Li Z, et al. The miR-25802/KLF4/NF-kappaB signaling axis regulates microglia-mediated neuroinflammation in Alzheimer’s disease. Brain Behav Immun. 2024;118:31–48.
Wang Y, Cui Y, Liu J, Song Q, Cao M, Hou Y, et al. Kruppel-like factor 5 accelerates the pathogenesis of Alzheimer’s disease via BACE1-mediated APP processing. Alzheimers Res Ther. 2022;14:103.
Besnard A, Langberg T, Levinson S, Chu D, Vicidomini C, Scobie KN, et al. Targeting Kruppel-like Factor 9 in excitatory neurons protects against chronic stress-induced impairments in dendritic spines and fear responses. Cell Rep. 2018;23:3183–96.
